Cross-Disease Multi-Omics Analysis of Autoimmune and Autoinflammatory Disorders to Elucidate Pathogenic Mechanisms and Identify Stratification Biomarkers
Conditions
Interventions
None listed
Sponsors
Nagasaki University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants must meet all of the following criteria Adult patients over 18 years old at the time of informed consent diagnosed with one of the following diseases Systemic lupus erythematosus, Rheumatoid arthritis, Idiopathic inflammatory myopathies, Hereditary muscle diseases, muscular dystrophy, congenital myopathies, metabolic muscle diseases, etc., Systemic sclerosis, Sjogrens disease, IgG4 related disease, ANCA associated vasculitis, microscopic polyangiitis, polyangiitis nodosa, eosinophilic polyangiitis, Other vasculitis syndromes, giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, IgA vasculitis, cryoglobulinemic vasculitis, antiglomerular basement membrane disease, Nephritic syndromes, tubulointerstitial nephritis, and metabolic kidney diseases, Castleman disease, TAFRO syndrome, Familial Mediterranean fever, Adult-onset Stills disease, CAPS, TRAPS, PFAPA syndrome, VEXAS syndrome, Psoriasis and psoriatic arthritis, Discoid lupus erythematosus, psoriasiform dermatitis, atopic dermatitis, vitiligo, prurigo, idiopathic acquired generalized anhidrosis, pyoderma gangrenosum, urticaria, angioedema, alopecia areata, hypertrophic dermoperiosteitis, elastic fiber pseudoxanthoma, serpiginous perforating elastic fiberosis, cutaneous lymphoma, Pemphigus, pemphigoid, and mucosal pemphigoid. Individuals who received a written explanation regarding the purpose and content of this study and provided their written consent, excluding those eligible for opt out.
Exclusion criteria
Exclusion criteria: 1. Patients judged by the attending physician to lack the capacity to provide informed consent 2. Patients considered inappropriate for participation in this study by the principal investigator or sub-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Characteristics of immunological abnormality clusters (cell populations, protein signatures, autoantibody signatures, and chronic oral inflammation-related signatures) common to multiple diseases, as identified through flow cytometry, proteomics analysis, PhIP-seq analysis, and analysis of antibody titers against periodontal disease-associated bacteria 2. Disease-specific immunological characteristics (cell subsets, gene expression patterns, protein signatures, autoantibody profiles, and oral inflammation-associated antibody profiles) identified through multi-omics analysis (flow cytometry, proteomics, PhIP-seq, scRNA-seq, periodontal disease-associated bacterial antibody titer analysis, etc.) 3. Identification of multi-omics biomarkers (Olink, scRNA-seq, PhIP-seq, antibody titers against periodontal disease-associated bacteria, etc.) to predict treatment response to biologics, molecularly targeted drugs, and other therapies 4. Elucidation of the association between serum antibody titers against periodontal disease-associated bacteria and disease activity in patients with autoimmune and autoinflammatory diseases (target bacteria: Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum) | — |
Countries
Japan
Contacts
Public ContactRemi Sumiyoshi
Nagasaki University Hospital Department of Immunology and Rheumatology
Outcome results
None listed